Showing 831-840 of 2062 results for "".
How Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiDermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workWhat Every Dermatologist Must Know About the History of Black Hair
https://practicaldermatology.com/topics/hair-nails/what-every-dermatologist-must-know-about-the-history-of-black-hair/23996/Knowledge of the historical, cultural, and social significance of hairstyles of Black patients may reduce implicit bias amongst dermatologists. In this article, Brooke Jackson, MD, FAAD, and Aliya Rodriguez, BS, explore the unique history and cultral impact of black hair.Skin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Advances in Understanding the Skin’s Microbiome
https://practicaldermatology.com/series/dermatology-dispatches/advances-in-understanding-the-skins-microbiome/19772/A growing body of evidence suggests that cutaneous dysbiosis plays a role in atopic dermatitis, psoriasis, acne, and rosacea, explains Adam Friedman, MD. Efforts to encourage diversity in the skin’s microbiome with pre- and probiotics may change the way dermatologists treat these diseases in the futFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuTherapeutics Update: Exploring Current Treatments for Diverse Conditions
https://practicaldermatology.com/topics/therapeutics-update/therapeutics-update-exploring-current-treatments-diverse-conditions/24562/Chief Medical Editor Neal Bhatia, MD, FAAD, and the Practical Dermatology® team convened an expert roundtable to discuss therapeutic treatment strategies for vitiligo, alopecia areata, hidradenitis suppurativa, and chronic spontaneous urticaria—the latest options, what has fallen out of favor, challCSF 2022 Highlights
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/csf-2022-highlights/20162/Joel Schlessinger, MD says the 2022 Cosmetic Surgery Forum was a success. The unique format of the meeting encourages presenters and audience members to interact and engage in lively discussions that allow attendees to leave the meeting with ideas they can use in their practices immediately.New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tCOVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-